AUTL Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals PLC has a net margin of -95193.1% compared to Autolus Therapeutics PLC's net margin of --. Autolus Therapeutics PLC's return on equity of -51.91% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Autolus Therapeutics PLC has a consensus price target of $10.21, signalling upside risk potential of 515.13%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 1370.86%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Autolus Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Autolus Therapeutics PLC.

Autolus Therapeutics PLC has a beta of 2.067, which suggesting that the stock is 106.723% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.

Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Autolus Therapeutics PLC quarterly revenues are $29K, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Autolus Therapeutics PLC's net income of -$27.6M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus 1.11x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -95193.1% compared to Autolus Therapeutics PLC's net margin of --. Autolus Therapeutics PLC's return on equity of -51.91% beat DBV Technologies SA's return on equity of --.

Autolus Therapeutics PLC has a consensus price target of $10.21, signalling upside risk potential of 515.13%. On the other hand DBV Technologies SA has an analysts' consensus of $22.63 which suggests that it could grow by 264.99%. Given that Autolus Therapeutics PLC has higher upside potential than DBV Technologies SA, analysts believe Autolus Therapeutics PLC is more attractive than DBV Technologies SA.

Autolus Therapeutics PLC has a beta of 2.067, which suggesting that the stock is 106.723% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.707, suggesting its less volatile than the S&P 500 by 29.271%.

Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Autolus Therapeutics PLC quarterly revenues are $29K, which are larger than DBV Technologies SA quarterly revenues of --. Autolus Therapeutics PLC's net income of -$27.6M is lower than DBV Technologies SA's net income of -$23M. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

NuCana PLC has a net margin of -95193.1% compared to Autolus Therapeutics PLC's net margin of --. Autolus Therapeutics PLC's return on equity of -51.91% beat NuCana PLC's return on equity of --.

Autolus Therapeutics PLC has a consensus price target of $10.21, signalling upside risk potential of 515.13%. On the other hand NuCana PLC has an analysts' consensus of $64.50 which suggests that it could grow by 4939.06%. Given that NuCana PLC has higher upside potential than Autolus Therapeutics PLC, analysts believe NuCana PLC is more attractive than Autolus Therapeutics PLC.

Autolus Therapeutics PLC has a beta of 2.067, which suggesting that the stock is 106.723% more volatile than S&P 500. In comparison NuCana PLC has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.789%.

Autolus Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.

Autolus Therapeutics PLC quarterly revenues are $29K, which are larger than NuCana PLC quarterly revenues of --. Autolus Therapeutics PLC's net income of -$27.6M is lower than NuCana PLC's net income of -$836.1K. Notably, Autolus Therapeutics PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics PLC is -- versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.